These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31908953)

  • 1. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats.
    Janson J; Andersson G; Bergquist L; Eriksson M; Folgering JHA
    Mol Genet Metab Rep; 2020 Mar; 22():100554. PubMed ID: 31908953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
    Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
    Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.
    Haurigot V; Marcó S; Ribera A; Garcia M; Ruzo A; Villacampa P; Ayuso E; Añor S; Andaluz A; Pineda M; García-Fructuoso G; Molas M; Maggioni L; Muñoz S; Motas S; Ruberte J; Mingozzi F; Pumarola M; Bosch F
    J Clin Invest; 2013 Aug; 123(8):3254-3271. PubMed ID: 23863627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
    Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys.
    Pinkstaff J; McCullagh E; Grover A; Melton AC; Cherukuri A; Wait JC; Nguyen A; Butt MT; Trombley JL; Reed RP; Adams EL; Boyd RB; Chandra S; Henshaw J; O'Neill CA; Zanelli E; Kovalchin J
    Toxicol Rep; 2023; 10():357-366. PubMed ID: 36923444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse.
    Urayama A; Grubb JH; Sly WS; Banks WA
    Mol Ther; 2008 Jul; 16(7):1261-6. PubMed ID: 18443601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
    Hemsley KM; King B; Hopwood JJ
    Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2014 Aug; 11(8):2928-34. PubMed ID: 24949884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
    Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of recombinant murine sulfamidase.
    Gliddon BL; Yogalingam G; Hopwood JJ
    Mol Genet Metab; 2004 Nov; 83(3):239-45. PubMed ID: 15542395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.